Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2025)

Anaptysbio's Total Non-Current Liabilities history spans 10 years, with the latest figure at $50.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 14.92% year-over-year to $50.7 million; the TTM value through Dec 2025 reached $50.7 million, down 14.92%, while the annual FY2025 figure was $50.7 million, 14.92% down from the prior year.
  • Total Non-Current Liabilities reached $50.7 million in Q4 2025 per ANAB's latest filing, roughly flat from $50.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $305.9 million in Q3 2022 to a low of $35.5 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $65.4 million, with a median of $53.2 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: surged 79.35% in 2021, then crashed 81.8% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $35.5 million in 2021, then rose by 23.4% to $43.9 million in 2022, then grew by 21.91% to $53.5 million in 2023, then increased by 11.33% to $59.5 million in 2024, then decreased by 14.92% to $50.7 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Total Non-Current Liabilities are $50.7 million (Q4 2025), $50.7 million (Q3 2025), and $48.6 million (Q2 2025).